This site is intended for healthcare professionals only

Diabetes Digest


Early View

Share this article

Day-and-night closed-loop insulin delivery in pregnancy

Devices and technology – October 2018 digest.
A randomised crossover trial of Cambridge University’s “artificial pancreas” in pregnant women with type 1 diabetes.

Stewart ZA, Wilinska ME, Hartnell S et al (2018) Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: a randomized controlled crossover trial. Diabetes Care 41: 1391–9

  • This open-label, randomised, two-period crossover trial evaluated the safety and efficacy of the Florence D2A, the fully closed-loop insulin system under development at the University of Cambridge.
  • A total of 16 pregnant women with type 1 diabetes, with gestational age between 8 and 24 weeks, were randomised to day-and-night use of either sensor-augmented pump (SAP) therapy or the closed-loop system for 4 weeks, before switching to the other therapy after a 1–2-week washout period. NICE-recommended blood glucose targets were used and there were not restrictions on diet, exercise or travel, and no remote monitoring took place.
  • The results showed no difference in the amount of time spent in the target glycaemic range between closed-loop and SAP therapy (62.3% vs 60.1%). There were also no differences in mean blood glucose, time spent in hyperglycaemia or HbA1c.
  • However, there were fewer episodes of hypoglycaemia (blood glucose <3.5 mmol/L) in the closed-loop arm (median 8.0 vs 12.5; P=0.04), and less time was spent hypoglycaemic (1.6% vs 2.7%). There were no episodes of severe hypoglycaemia in either group.
  • No serious adverse events occurred, but there were often device malfunctions in the closed-loop arm. Despite this, all participants chose to continue using the device for at least some time after the trial ended (the device was offered up to 6 weeks postpartum). During this period, the median time in target range was around 70%.
  • Some individual variation in response to the closed-loop system was observed, with five participants (31%) having worse glycaemic control whilst on the intervention. Despite this, these participants elected to continue using the closed-loop system after the trial.
  • Regarding neonatal outcomes, the participants delivered at a median gestation of 36.9 weeks, 13 by caesarean section. Eleven infants (69%) were admitted to intensive care, seven of whom (44%) were treated for hypoglycaemia. Seven infants (44%) were large for gestational age. Two infants had congenital abnormalities.
  • The authors conclude that day-and-night closed-loop insulin delivery was effective in pregnant women with type 1 diabetes, and potentially safer as it was associated with less hypoglycaemia that SAP therapy. Larger, longer-duration trials are planned.

Click here to access the article in full.

Related content
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.